Cytokine comparisons between women with breast cancer and women with a negative breast biopsy

Nursing Research

Volumn 57, Issue 1, 2008, Pages 51-58

  Lyon, Debra E ^a   McCain, Nancy L ^a   Walter, Jeanne ^a   Schubert, Christine ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Bioplex; Breast cancer; Cytokines

Indexed keywords

CYTOKINE; TUMOR MARKER;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HUMAN; MIDDLE AGED; ROC CURVE;

ADULT; AREA UNDER CURVE; BREAST NEOPLASMS; CYTOKINES; FEMALE; HUMANS; MIDDLE AGED; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 37349065520     PISSN: 00296562     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.NNR.0000280655.58266.6c     Document Type: Article

References (28)

1. Aggarwal, S., & Gurney, A. L. (2002). IL-17: Prototype member of an emerging cytokine family. Journal of Leukococyte Biology, 71(1), 1-8.
2. Alexandrakis, M. G., Pappa, C. A., Miyakis, S., Sfiridaki, A., Kafousi, M., Alegakis A., et al. (2006). Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma. European Journal of Internal Medicine, 17(6), 412-416.
3. Bachelot, T., Ray-Coquard, I., Menetrier-Caux, C., Rastkha, M., Duc, A., & Blay, J. Y. (2003). Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. British Journal of Cancer, 88(11), 1721-1726.
4. Balkwill, F., & Mantovani, A. (2001). Inflammation and cancer: Back to Virchow? Lancet, 357(9255), 539-545.
5. Ben-Baruch, A. (2003). Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression: Reciprocal tumor - microenvironment interactions. Breast Cancer Research, 5(1), 31-36.
6. Ben-Baruch, A. (2006). Inflammation-associated immune suppression in cancer: The roles played by cytokines, chemokines and additional mediators. Seminars in Cancer Biology, 16(1) 38-52.
7. Benoy, I., Salgado, R., Van Dam P., Geboers K., Van Marck E., Scharpe S., et al. (2004). Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clinical Cancer Research, 10(21), 7157-7162.
8. Bower, J., Ganz, P., Desmond, K., Rowland, J., Meyerowitz, B. E., & Belin, T. R. (2000). Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. Journal of Clinical Oncology, 18(4), 743-753.
9. Campbell, G. (1994). Advances in statistical methodology for the evaluation of diagnostic and laboratory tests. Statistics in Medicine, 13(5-7), 499-508.
10. Cohen, N. (2004). Biological relevance of data variability. Brain, Behavior, and Immunity, 18(6), 495-496.
11. Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. Nature, 420(6917), 860-867.
12. Dinarello, C. A. (2000). Proinflammatory cytokines. Chest, 118(2), 503-508.
13. Duffy, M. J. (2001). Biochemical markers in breast cancer: Which ones are clinically useful? Clinical Biochemistry, 34(5), 347-352.
14. Fossiez, F., Djossou, O., Chomarat, P., Flores-Romo, L., Ait-Yahia, S., Maat, C., et al. (1996). T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. Journal of Experimental Medicine, 183(6), 2593-2603.
15. Gorelik, E., Landsittel, D. P., Marrangoni, A. M., Modugno, F., Velikokhatnaya, L., Winans, M. T., et al. (2005). Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention, 14(4), 981-987.
16. Kato, T., Furumoto, H., Ogura, T., Onishi, Y., Irahara, M., Yamano, S., et al. (2001). Expression of IL-17 mRNA in ovarian cancer. Biochemical and Biophysical Research Communications, 282(3), 735-738.
17. Kofoed, K., Schneider, U., Scheel, T., Andersen, O., & Eugen-Olsen, J. L. (2006). Development and validation of a multiplex add-an assay for sepsis biomarkers using xMAP technology. Clinical Chemistry, 52(7), 1284-1293.
18. Lawicki, S., Szmitkowski, M., & Wojtukiewicz, M. (2006). The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. Clinica Chimica Acta, 371(1-2), 112-116.
19. Leek, R., & Harris, A. (2002). Tumor-associated macrophages in breast cancer. Journal of Mammary Gland Biology and Neoplasia, 7(2), 177-189.
20. Liu, H., Li, G., Cumberland, W. G., & Wu, T. (2005). Testing statistical significance of the area under a receiving operating characteristics curve for repeated measures design with bootstrapping. Journal of Data Science, 3(3), 257-278.
21. McCain, N. L., Gray, D. P., Walter, J. M., & Robins, J. (2005). Implementing a comprehensive approach to the study of health dynamics using the psychoneuroimmunology paradigm. Advances in Nursing Science, 28(4), 320-32.
22. Mettler, L., Salmassi, A., Heyer, M., Schmutzier, A., Schollmeyer, T., & Jonat, W. (2004). Perioperative levels of interleukin-1 beta and interleukin-6 in women with breast cancer. Clinical and Experimental Obstetrics & Gynecology, 31(1), 20-22.
23. Morgan, E., Varro, R., Sepulveda, H., Ember, J. A., Apgar, J., Wilson, J., et al. (2004). Cytometric bead array: A multiplexed assay platform with applications in various areas of biology. Clinical Immunology, 110(3), 252-266.
24. Musselman, D., Miller, A., Porter, M., Manatunga, A., Gao, F., Penna, S., et al. (2001). Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: Preliminary findings. American Journal of Psychiatry, 158(8), 1252-1257.
25. Numasaki, M., Fukushi, J., Ono, M., Narula S. K., Zavodny P. J., Kudo T., et al. (2003). Interleukin-17 promotes angiogenesis and tumor growth. Blood, 101(7), 2620-2627.
26. Rao, V., Dyer, C., Jameel, J., Drew, P., & Greenman, J. (2006). Potential prognostic and therapeutic roles for cytokines in breast cancer [Review]. Oncology Reports, 15(1), 179-185.
27. Thomson, A. W., & Lotze, M. T. (2003). The Cytokine Handbook. London: Academic Press.
28. Zhang, G. J, & Adachi, I. (1999). Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Research, 19(2B), 1427-1432.